A look at Isomorphic Labs, a life sciences startup spun out of Google DeepMind, both led by Demis Hassabis, aiming to “solve all disease” via AI drug discovery
They recently raised $600 million in external funding. Today, they made AlphaFold3 available to the scientific community. www.cnbc.com/2025/04/09/i... LinkedIn: Hayden Field : On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. — It wasn't his paycheck. …
Context & Ripple Effects
Isomorphic Labs was created as a Google DeepMind spinout, with Demis Hassabis holding leadership roles across both organizations; its new outside financing tests whether that structure can support an independently funded drug-discovery business.
The company had already moved from research toward commercial validation through drug-discovery partnerships with Eli Lilly and Novartis, while DeepMind and Isomorphic had described AlphaFold 3's ability to model molecular interactions. Making the model available broadens the research-facing side of that strategy.
First-order effects
- Isomorphic Labs gains $600 million of external capital to pursue its AI drug-discovery work, reducing its reliance on its DeepMind parent for funding.
- Scientists can now use AlphaFold 3, extending access to the underlying molecular-modeling capability beyond the company and its commercial partners.
Second-order effects
- The combination of external financing and scientific access raises the bar for AI drug-discovery rivals: they must show both credible research tools and a path to pharmaceutical collaboration.
- Existing and prospective pharma partners gain a wider ecosystem of researchers able to interrogate the same class of molecular predictions, potentially making validation and differentiation more central to partnership decisions.
Third-order effects
- If AI drug-discovery companies can pair frontier-model development with independent funding and pharma partnerships, the sector may consolidate around well-capitalized labs linked to major AI platforms rather than standalone software vendors.
- Broader model access could shift competition from exclusive access to prediction systems toward proprietary experimental data, drug-development execution, and evidence that predictions translate into useful medicines.
The trend: AI drug discovery is evolving from an internal frontier-lab research effort into a capital-intensive platform business that must balance broad scientific distribution with proprietary commercial development.